193 related articles for article (PubMed ID: 19864909)
41. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?
Leoni V; Shafaati M; Salomon A; Kivipelto M; Björkhem I; Wahlund LO
Neurosci Lett; 2006 Apr 10-17; 397(1-2):83-7. PubMed ID: 16406316
[TBL] [Abstract][Full Text] [Related]
42. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.
Arai H; Ishiguro K; Ohno H; Moriyama M; Itoh N; Okamura N; Matsui T; Morikawa Y; Horikawa E; Kohno H; Sasaki H; Imahori K
Exp Neurol; 2000 Nov; 166(1):201-3. PubMed ID: 11031097
[TBL] [Abstract][Full Text] [Related]
43. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.
Andersson C; Blennow K; Almkvist O; Andreasen N; Engfeldt P; Johansson SE; Lindau M; Eriksdotter-Jönhagen M
Neurobiol Aging; 2008 Oct; 29(10):1466-73. PubMed ID: 17512092
[TBL] [Abstract][Full Text] [Related]
44. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
45. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.
Ewers M; Buerger K; Teipel SJ; Scheltens P; Schröder J; Zinkowski RP; Bouwman FH; Schönknecht P; Schoonenboom NS; Andreasen N; Wallin A; DeBernardis JF; Kerkman DJ; Heindl B; Blennow K; Hampel H
Neurology; 2007 Dec; 69(24):2205-12. PubMed ID: 18071141
[TBL] [Abstract][Full Text] [Related]
46. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
47. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
[TBL] [Abstract][Full Text] [Related]
48. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.
van Rossum IA; Vos S; Handels R; Visser PJ
J Alzheimers Dis; 2010; 20(3):881-91. PubMed ID: 20413876
[TBL] [Abstract][Full Text] [Related]
49. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
[TBL] [Abstract][Full Text] [Related]
50. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.
Parnetti L; Lanari A; Saggese E; Spaccatini C; Gallai V
Neurol Sci; 2003 Oct; 24(3):199-200. PubMed ID: 14598086
[TBL] [Abstract][Full Text] [Related]
51. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
52. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease.
Perneczky R; Tsolakidou A; Arnold A; Diehl-Schmid J; Grimmer T; Förstl H; Kurz A; Alexopoulos P
Neurology; 2011 Jul; 77(1):35-8. PubMed ID: 21700579
[TBL] [Abstract][Full Text] [Related]
53. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
54. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
Brunnström H; Rawshani N; Zetterberg H; Blennow K; Minthon L; Passant U; Englund E
Alzheimers Dement; 2010 Mar; 6(2):104-9. PubMed ID: 20298970
[TBL] [Abstract][Full Text] [Related]
56. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
Fellgiebel A; Kojro E; Müller MJ; Scheurich A; Schmidt LG; Fahrenholz F
J Geriatr Psychiatry Neurol; 2009 Mar; 22(1):3-9. PubMed ID: 19073834
[TBL] [Abstract][Full Text] [Related]
57. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
Ivanoiu A; Sindic CJ
Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
[TBL] [Abstract][Full Text] [Related]
58. Inflammatory markers in AD and MCI patients with different biomarker profiles.
Schuitemaker A; Dik MG; Veerhuis R; Scheltens P; Schoonenboom NS; Hack CE; Blankenstein MA; Jonker C
Neurobiol Aging; 2009 Nov; 30(11):1885-9. PubMed ID: 18378357
[TBL] [Abstract][Full Text] [Related]
59. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].
Schonknecht P; Pantel J; Werle E; Hartmann T; Essig M; Baudendistel K; Beyreuther K; Schroder J
Fortschr Neurol Psychiatr; 2000 Oct; 68(10):439-46. PubMed ID: 11103680
[TBL] [Abstract][Full Text] [Related]
60. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
